
    
      This is an open-label, randomized, 3-stage, phase 2 study. Pts who have failed â‰¥2 prior CT
      regimens (including high-dose CT) will be randomized to receive one of the following: D, 1.5
      g via IV infusion q4w, for up to a total of 12 months (13 doses/cycles) alone or with T, 75
      mg IV q4w, starting on week 0, for up to 4 months (4 doses/cycles).
    
  